Tech Company Financing Transactions
Lusaris Therapeutics Funding Round
On 11/2/2022, Lusaris Therapeutics received $60 million in Series A funding from RA Capital, Boxer Capital and Deep Track Capital.
Transaction Overview
Company Name
Announced On
11/2/2022
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
RA Capital (Lead Investor) (Andrew Levin)
Proceeds Purpose
The company will use the funds to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Berkeley St 18th Fl
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
Lusaris was founded by a team of highly experienced drug developers and company builders with extensive neuroscience experience. Our drug development expertise, pipeline of potentially best-in-class neuropsychiatric and neurological therapeutics, and backing from a world-class investor syndicate uniquely position Lusaris to succeed in bringing life-changing medicines--and renewed hope--to millions of patients and their families.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Levin
Chief Financial Officer
Kat Riesen
Chief Operating Officer
Neil Buckley
Browse more venture capital transactions:
Prev: 11/2/2022: Alation venture capital transaction
Next: 11/2/2022: Orum venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs